SynthesisChronic respiratory disease
Prevalence and assessment of frailty in interstitial lung disease - a systematic review and meta-analysis.
Synthesis in Chronic respiratory disease. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 1 synthesis or guideline pooled it, 13 citations in OpenAlex.
- Clinical characteristics and mortality risk of sarcopenia in interstitial lung disease: a systematic review and meta-analysis.Frontiers in medicine · 2026Pooled it
- Peri-transplant frailty changes impact survival in interstitial lung diseases.ERJ open research · 2026Article
- An Age-Friendly Approach to Caring for Chronic Lung Disease in the Ambulatory Setting.Respirology (Carlton, Vic.) · 2026Review
- Analysis of risk factors for frailty in older inpatients with interstitial lung disease.BMC pulmonary medicine · 2026Article
- Resources in the bronchoscopy suite and the utility of cryobiopsy.African journal of thoracic and critical care medicine · 2025Article
- The relationship between respiratory symptoms and frailty: findings from observational and Mendelian randomization analyses.Aging clinical and experimental research · 2024Article
- Sarcopenia in interstitial lung disease.European respiratory review : an official journal of the European Respiratory Society · 2024Review
- Beyond Chronological Age: Aging and Senescence in Interstitial Lung Diseases.Open respiratory archivesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFrailty is a multisystem dysregulation that challenges homeostasis and increases vulnerability towards stressors. In patients with interstitial lung diseases (ILD) frailty is associated with poorer lung function, greater physical impairment, and higher symptom burden. Our understanding of the prevalence of frailty in ILD and consequently its impact on the ILD population is limited. OBJECTIVE AND
methodsWe aimed to systematically review frailty assessment tools and to determine frailty prevalence across different ILD cohorts. Meta-analyses were used to calculate the pooled prevalence of frailty in the ILD population.
resultsWe identified 26 studies (15 full-texts, 11 conference abstracts) including a total of 4614 patients with ILD. The most commonly used frailty assessment tools were the Fried Frailty Phenotype (FFP), the Short Physical Performance Battery (SPPB), and the cumulative Frailty Index (FI). Data allowed for meta-analyses of FFP and SPPB prevalence. The pooled prevalence of frailty was 35% (95% CI 25%-45%) by FFP, and 19% (95% CI 12%-28%) by SPPB.
conclusionsFrailty is common in ILD, with considerable variability of frailty prevalence depending on the frailty assessment tool used. These findings highlight the importance of frailty in ILD and the need for a standardized approach to frailty assessment in this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.